Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Depreciation and Depletion (2017 - 2019)

Historic Depreciation and Depletion for Arrowhead Pharmaceuticals (ARWR) over the last 3 years, with Q2 2019 value amounting to $578342.0.

  • Arrowhead Pharmaceuticals' Depreciation and Depletion fell 2300.42% to $578342.0 in Q2 2019 from the same period last year, while for Jun 2019 it was $2.9 million, marking a year-over-year change of. This contributed to the annual value of $3.0 million for FY2018, which is 29.55% up from last year.
  • As of Q2 2019, Arrowhead Pharmaceuticals' Depreciation and Depletion stood at $578342.0, which was down 2300.42% from $750860.0 recorded in Q1 2019.
  • Arrowhead Pharmaceuticals' 5-year Depreciation and Depletion high stood at $803288.0 for Q3 2018, and its period low was $578342.0 during Q2 2019.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Depreciation and Depletion value was $750860.0 (recorded in 2019), while the average stood at $725756.3.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Depreciation and Depletion surged by 505.25% in 2018 and then tumbled by 2300.42% in 2019.
  • Quarter analysis of 3 years shows Arrowhead Pharmaceuticals' Depreciation and Depletion stood at $716066.0 in 2017, then increased by 5.05% to $752245.0 in 2018, then dropped by 23.12% to $578342.0 in 2019.
  • Its last three reported values are $578342.0 in Q2 2019, $750860.0 for Q1 2019, and $752245.0 during Q4 2018.